426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg

Marcia S. Brose, Y. Panaseykin, Bhavana Konda, Christelle de la Fouchardière, Brett Hughes, Andrew G. Gianoukakis, Y.J. Park, I. Romanov, Monika K. Krzyzanowska, T. Binder, Corina E. Dutcus, Ran Xie, Matthew H. Taylor